Repositioning of a Novel GABA-B Receptor Agonist, AZD3355 (Lesogaberan), for the Treatment of Non-Alcoholic Steatohepatitis

Lesogaberan’s potential efficacy in non-alcoholic steatohepatitis (NASH) was tested in human stellate cells, human precision cut liver slices, and in vivo in a well-validated murine model of NASH.